Prolongation and quality of life for HIV-infected adults treated with highly active antiretroviral therapy (HAART): A balancing act

被引：69

作者：

Burgoyne, Robert W. ^{[1
,2
]}

Tan, Darrell H. S. ^{[3
]}

机构：

[1] Univ Toronto, Immunodeficiency Clin, Univ Hlth Network, Toronto, ON M5G 2C4, Canada

[2] Univ Toronto, Dept Psychiat, Toronto, ON M5G 2C4, Canada

[3] Univ Toronto, Div Infect Dis, Toronto, ON M5G 2C4, Canada

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2008年 / 61卷 / 03期

关键词：

AIDS; drug toxicities; QOL;

D O I：

10.1093/jac/dkm499

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Advances in highly active antiretroviral therapy (HAART) options for people living with HIV/AIDS have resulted in decreased morbidity and mortality. To some extent, the role of disease progression in eroding quality of life (QOL) erosion in the pre-HAART age is now supplanted by drug toxicities, one of the Achilles' heels of HAART. This article reviews research findings on treatment and QOL outcomes a decade into the HAART era.

引用

页码：469 / 473

页数：5

共 65 条

[21] Treatment for adult HIV infection - 2006 recommendations of the International AIDS Society-USA panel [J].

Hammer, Scott M. ;

Saag, Michael S. ;

Schechter, Mauro ;

Montaner, Julio S. G. ;

Schooley, Robert T. ;

Jacobsen, Donna M. ;

Thompson, Melanie A. ;

Carpenter, Charles C. J. ;

Fischl, Margaret A. ;

Gazzard, Brian G. ;

Gatell, Jose M. ;

Hirsch, Martin S. ;

Katzenstein, David A. ;

Richman, Douglas D. ;

Vella, Stefano ;

Yeni, Patrick G. ;

Volberding, Paul A. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (07) :827-843

[22] Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector) [J].

Harris, M ;

Joy, R ;

Larsen, G ;

Valyi, M ;

Walker, E ;

Frick, LW ;

Palmatier, RM ;

Wring, SA ;

Montaner, JSG .

AIDS, 2006, 20 (05) :719-723

[23] Maternal toxicity with continuous nevirapine in pregnancy - Results from PACTG 1022 [J].

Hitti, J ;

Frenkel, LM ;

Stek, AM ;

Nachman, SA ;

Baker, D ;

Gonzalez-Garcia, A ;

Provisor, A ;

Thorpe, EM ;

Paul, ME ;

Foca, M ;

Gandia, J ;

Huang, S ;

Wei, LJ ;

Stevens, LM ;

Watts, DH ;

McNamara, J .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 36 (03) :772-776

[24] Improved survival among HIV-infected individuals following initiation of antiretroviral therapy [J].

Hogg, RS ;

Heath, KV ;

Yip, B ;

Craib, KJP ;

O'Shaughnessy, MV ;

Schechter, MT ;

Montaner, JSG .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (06) :450-454

[25] 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures [J].

Johnson, M ;

Grinsztejn, B ;

Rodriguez, C ;

Coco, J ;

DeJesus, E ;

Lazzarin, A ;

Lichtenstein, K ;

Wirtz, V ;

Righmire, A ;

Odeshoo, L ;

McLaren, C .

AIDS, 2006, 20 (05) :711-718

[26]

Lochet P, 2003, HIV Med, V4, P62, DOI 10.1046/j.1468-1293.2003.00136.x

[27] Changes in symptoms and health-related quality of life in a nationally representative sample of adults in treatment for HIV [J].

Lorenz, Karl A. ;

Cunningham, William E. ;

Spritzer, Karen L. ;

Hays, Ron D. .

QUALITY OF LIFE RESEARCH, 2006, 15 (06) :951-958

[28] Health related quality of life among persons with HIV after the use of protease inhibitors [J].

Low-Beer, S ;

Chan, K ;

Wood, E ;

Yip, B ;

Montaner, JSG ;

O'Shaughnessy, MV ;

Hogg, RS .

QUALITY OF LIFE RESEARCH, 2000, 9 (08) :941-949

[29] Assessment of quality of life in early stage HIV-infected persons: data from the AIDS Time-Oriented Health Outcome Study (ATHOS) [J].

Lubeck, DP ;

Fries, JF .

QUALITY OF LIFE RESEARCH, 1997, 6 (06) :494-506

[30]

LUBECK DP, 1993, J ACQ IMMUN DEF SYND, V6, P478

← 1 2 3 4 5 6 7 →